Novo Nordisk (NVO) Soars 3.39% on Wegovy Sales Surge

On April 29, 2025, Novo Nordisk's stock rose by 3.39% in pre-market trading, reflecting positive market sentiment towards the company's recent developments and financial performance.

Novo Nordisk, a leading player in the weight loss drug market, has seen its stock price surge following the release of its third-quarter financial results. The company's flagship weight loss drug, Wegovy, reported strong sales figures, exceeding market expectations. Wegovy's sales reached 173.04 billion Danish kroner, a 79% year-over-year increase, driven by growing insurance coverage and increased demand in the U.S. market. This performance has led Novo Nordisk to raise its full-year guidance, projecting a 23-27% increase in sales and a 21-27% increase in operating profit for 2024.

In addition to Wegovy, Novo Nordisk is also developing several other promising weight loss drugs. One of the most anticipated is CagriSema, a combination drug that includes semaglutide and cagrilintide. CagriSema is expected to achieve at least a 25% weight loss effect without additional side effects, addressing the issue of weight rebound after stopping the drug. The company has also submitted an application to the FDA for a 25mg oral version of semaglutide, which has shown promising results in clinical trials, with a 17.4% weight loss over 68 weeks. This oral version is expected to provide a more convenient treatment option for patients, potentially expanding the market for weight loss drugs.